09:47 AM EDT, 07/22/2025 (MT Newswires) -- Arch Biopartners ( ACHFF ) on Tuesday said it has begun enrolling patients for its Phase 2 study investigating cilastatin's role in preventing acute kidney injury that is associated with certain pharmaceuticals.

The Pontiak trial plans to enrol about 698 patients in five hospital sites in Alberta.

Arch Biopartners ( ACHFF ) recently manufactured the first-ever, stand-alone cilastatin drug product and is supplying the drug for the trial. While the trial is investigator-led and independently funded, Arch is also evaluating opportunities to support a complementary arm of the study in the United States.

The company's shares are down $0.05, to $1.70, on the TSX Venture Exchange.

Price: 1.70, Change: -0.05, Percent Change: -2.86